Drug news
Keryx Biopharma returns North American rights to Aeterna Zentaris for perifosine
Keryx BioPharma has returned North American rights to Aeterna Zentaris for the oral anticancer Akt inhibitor, perifosine � a Phase III-stage compound. A Phase III trial called X-PECT evaluating perifosine plus Xeloda (capecitabine) showed a failure to meet the primary endpoint of improving overall survival compared to Xeloda and placebo in the treatment of refractory Colorectal Cancer.The drug remains in trials for Multiple Myeloma.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.